Research location

Hannibal

Missouri, United States

Published trials18
Site observations18
Linked trials published18
Page1 / 1
Advertisement

Research activity in Hannibal

Missouri, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 18 trials and 18 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Hannibal

18 linked trials · page 1 of 1
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeNCT07190222 · 2025-09-17 · 1 site observation
RECRUITING
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary HypertensionNCT06911632 · 2025-07-23 · 1 site observation
RECRUITING
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT07082738 · 2025-06-27 · 1 site observation
RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)NCT06878261 · 2025-03-25 · 1 site observation
RECRUITING
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · 2024-11-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 · 2024-04-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306 · 2024-01-11 · 1 site observation
COMPLETED
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086 · 2023-09-22 · 1 site observation
COMPLETED
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier DetectionNCT05776225 · 2023-08-11 · 1 site observation
COMPLETED
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT05878769 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in LungNCT05306288 · 2022-04-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05037929 · 2021-10-05 · 1 site observation
COMPLETED
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663 · 2021-05-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04701983 · 2020-12-16 · 1 site observation
COMPLETED
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)NCT04609878 · 2020-12-15 · 1 site observation
COMPLETED
A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular DiseaseNCT03936660 · 2019-07-25 · 1 site observation
COMPLETED
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)NCT00443443 · 2007-01-01 · 1 site observation
COMPLETED
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.